Pharmaceuticals: Major · attribution context sourced from stored price moves, stored event labels, and peer-relative residuals inside the XLV constituent company universe.
Review priority 100 · Source rank 0 · Volume 14.9x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +0.12% · Sector -1.36% · Industry -0.74% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -18.71%Review priority 88 · Source rank 0 · Volume 4.3x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +1.63% · Sector +0.13% · Industry -1.10% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +12.57%Review priority 83 · Source rank 0 · Volume 8.5x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +0.42% · Sector -0.51% · Industry -0.32% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -10.55%Review priority 79 · Source rank 0 · Volume 3.4x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -1.86% · Sector +1.63% · Industry +0.44% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +9.45%Review priority 72 · Source rank 54 · Volume 2.3x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +2.68% · Sector -1.83% · Industry -0.27% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +8.45%Review priority 69 · Source rank 0 · Volume 2.3x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -1.06% · Sector +1.25% · Industry +1.09% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +7.03%Review priority 67 · Source rank 54 · Volume 2.1x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +8.14% · Sector -6.08% · Industry -0.59% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +6.76%Review priority 64 · Source rank 54 · Volume 1.1x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +10.27% · Sector -4.63% · Industry -2.12% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +6.82%| Date | Label | Move | Residual after context | Scope | Confidence |
|---|---|---|---|---|---|
| Oct 28, 2022 | Broad market moved +2.68% with this stock | +9.03% | +8.45% | Macro | 58% |
| Mar 13, 2020 | Broad market moved +8.14% with this stock | +8.23% | +6.76% | Macro | 58% |
| Mar 24, 2020 | Broad market moved +10.27% with this stock | +10.35% | +6.82% | Macro | 58% |
| Mar 16, 2020 | Broad market moved -12.04% with this stock | -9.55% | -5.23% | Macro | 58% |
| Aug 5, 2025 | Vertex Pharmaceuticals Incorporated 10-Q: 10-Q | -20.60% | +0.67% | Direct | 70% |
| Aug 5, 2025 | Vertex Pharmaceuticals Incorporated 8-K: 8-K | -20.60% | +0.67% | Direct | 70% |
| Aug 5, 2025 | NASDAQ:VRTX quarterly report filing | -20.60% | +0.67% | Direct | 94% |
| Dec 19, 2024 | Vertex Pharmaceuticals Incorporated 8-K: 8-K | -11.37% | -0.96% | Direct | 70% |
| Dec 19, 2024 | NASDAQ:VRTX 8-K current report items 7.01 | -11.37% | -0.96% | Direct | 94% |
| May 6, 2025 | Vertex Pharmaceuticals Incorporated 10-Q: 10-Q | -10.03% | -2.28% | Direct | 70% |